Summary: Dr. Mahdavi’s talk reviews key growth areas, innovative technologies and future strategies designed to increase the efficiency and scalability of advanced therapeutics.

Summary: In this webinar, leaders in the field discuss new vaccines and drugs that have resulted from COVID and key learnings to prepare for the next pandemic.

Summary: This roundtable discussion offers a closer look at oncology's hottest fields, including CAR-T and precision medicine, 2021's biggest research trends and the data they're most looking forward to seeing.

Summary: In this webinar executive summary, industry experts share diverse insights about challenges and opportunities with repurposing drugs for new disease treatments.

Summary: Experts discuss the changing experience from the last quarter of a century in the pathway to patients, and how the latest advanced technologies translate into effective pre-clinical and clinical development and manufacturing.

Summary: Catalent has developed a relative potency bioassay using real-time quantitative reverse transcription (RT-qPCR) in a duplex format to assess relative transcription activity in cells treated with ligands or transgenic vectors.

Summary: The GPEx® suite of cell line development technologies has been utilized to develop hundreds of proteins, including difficult-to-express proteins, in a variety of mammalian cell lines.

Summary: In a panel discussion executives from Moderna, Sanofi Pasteur, Takeda and Catalent share behind-the-scenes updates on their respective efforts to develop a COVID-19 vaccine.

Summary: There has been a lot of activity in the ADC market in the past 12-18 months in terms of licensing deals, acquisitions and investments. It’s likely no coincidence that this...

Summary: Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.